Prolight Diagnostics presents the Psyros system at ADLM, one of the world’s largest and most important diagnostics congresses

Prolight Diagnostics (“Prolight”), developer of the Psyros™ digital point-of-care (POC) system for high-sensitivity troponin, announces that the platform will be showcased at DxPxduring the international congress ADLM in Chicago July 28-August 1, 2024. “We are very proud to present the latest commercial instrument prototype and the cartridge that will be used for high-sensitivity troponin assays. […]

Annual general meeting of Prolight Diagnostics AB (publ) on 27 May 2024

The annual general meeting (AGM) of Prolight Diagnostics AB (publ) took place on 27 May 2024 in Lund. Full information regarding the decisions of the AGM is available on the company’s website, The AGM resolved in accordance with all of the motions presented in the notification of the AGM. Resolution regarding the adoption of […]

Prolight on track for clinical performance studies

Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, announces today that their latest data for troponin in whole blood confirm that the company is now ready to initiate trials with patient samples. The latest data were generated in whole blood samples on the final commercial cartridge design, which now includes internal cartridge quality controls […]

Prolight initiates trial at London hospital Trust supported by an NIHR i4i PDA grant

Prolight Diagnostics today announces the company will initiate a trial at Guy’s and St Thomas’NHS Foundation Trust and King’s College London to pre-validate assay and prototype performance of the Psyros™ POC system. The trial is supported by the recently awarded NIHR i4i PDA grant. Initial data with patient samples will be generated in Q3 2024 […]

Prolight Diagnostics awarded SEK17M UK government grant in collaboration with leading UK hospital Trust

Prolight Diagnostics, developer of the digital point-of-care platform PsyrosTM, has been awarded an NIHR Invention for Innovation (i4i) Product Development Award (PDA) of SEK17M (£1.26M) in collaboration with among others, Guy’s and St Thomas’ NHS Foundation Trust, and King’s College London. “We are delighted to have been awarded this prestigious grant. The National Institute for […]

Prolight selects MDx CRO for the clinical performance studies for Psyros™

Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, has appointed MDx CRO as its contract research partner for the clinical performance study to validate the Psyros™ high-sensitivity troponin test. After a rigorous selection process, Prolight is pleased to announce the appointment of MDxCRO as its clinical partner. The collaboration will focus on the clinical validation […]


The Company has decided to move the annual general meeting to 27 May 2024. The new notice is stated below, which also replaces the previously published notice. The Company has also decided to move the publication of the Company’s interim report for Q1 to 17 May 2024. The shareholders in Prolight Diagnostics AB (publ), corp. […]

Emergers publishes updated analysis about Prolight Diagnostics

Read the full article at: For further information, please contact:Prolight Diagnostics AB (publ)E-mail: info@prolightdx.comTelephone: +46 73 582 39 87Website: About UsProlight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.We want to offer the foremost POC […]

Prolight finalizes commercial cartridge design

Prolight Diagnostics AB (publ), developer of the digital point-of-care platform Psyros™, today announces the finalization of the cartridge design to be used on the commercial platform. Now, the process of design transfer to Prolight’s contract manufacturing partner Flex Medical Solutions begins. Flex Medical will use the design for the pilot manufacturing processes which shall be be […]